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Introduction: Breast cancer staging with sentinel lymph node biopsy relies on the use of 
radioisotopes, which limits the availability of the procedure worldwide. The use of a magnetic 
nanoparticle tracer and a handheld magnetometer provides a radiation-free alternative, which 
was recently evaluated in two clinical trials. The hydrodynamic particle size of the used magnetic 
tracer differs substantially from the radioisotope tracer and could therefore benefit from optimi-
zation. The aim of this study was to assess the performance of three different-sized magnetic 
nanoparticle tracers for sentinel lymph node biopsy within an in vivo porcine model.
Materials and methods: Sentinel lymph node biopsy was performed within a validated porcine 
model using three magnetic nanoparticle tracers, approved for use in humans (ferumoxytol, 
with hydrodynamic diameter d
H
 =32 nm; Sienna+®, d
H
 =59 nm; and ferumoxide, d
H
 =111 nm), 
and a handheld magnetometer. Magnetometer counts (transcutaneous and ex vivo), iron quan-
tification (vibrating sample magnetometry), and histopathological assessments were performed 
on all ex vivo nodes.
Results: Transcutaneous “hotspots” were present in 12/12 cases within 30 minutes of injec-
tion for the 59 nm tracer, compared to 7/12 for the 32 nm tracer and 8/12 for the 111 nm 
tracer, at the same time point. Ex vivo magnetometer counts were significantly greater for 
the 59 nm tracer than for the other tracers. Significantly more nodes per basin were excised for the 
32 nm tracer compared to other tracers, indicating poor retention of the 32 nm tracer. Using the 
59 nm tracer resulted in a significantly higher iron accumulation compared to the 32 nm tracer.
Conclusion: The 59 nm tracer demonstrated rapid lymphatic uptake, retention in the first 
nodes reached, and accumulation in high concentration, making it the most suitable tracer for 
intraoperative sentinel lymph node localization.
Keywords: superparamagnetic iron oxide, breast cancer, magnetic tracer, ferumoxytol, feru-
moxide, Sienna+®
Introduction
Breast cancer is the most common cancer among women, with approximately 
1.67 million new patients diagnosed annually worldwide and accounting for 25% of 
all cancer cases.1 Breast cancer predominantly spreads via the lymphatic system to 
locoregional lymph nodes, meaning that the status of these lymph nodes is important 
for staging of the disease and determining prognosis.2–4
The sentinel lymph nodes (SLNs) are defined as the first draining nodes from a 
primary tumor and, therefore, are most likely to be the first site of lymphatic metastasis. 
Sentinel lymph node biopsy (SLNB) with the “combined technique” of radioisotope 
and blue dye is the standard method for determining axillary staging in early-stage 
breast cancer patients with a clinically and radiologically negative axilla.3,5–9
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The combined technique is performed by injecting a 
radioactive tracer (99mTc nanocolloid) and blue dye intersti-
tially, either peritumorally or periareolarly. The tracers are 
distributed through the lymphatic system, to the draining 
SLNs. The tracers are then detected within the SLNs by the 
surgeon using a handheld scintillation counter (gamma probe) 
and/or visually. The gamma probe is first used to transcutane-
ously localize the SLNs and determine the optimal incision 
site. Postincision both the blue dye and gamma probe guide 
the surgeon to the SLNs. After identification, the SLNs are 
removed and sent for histopathological examination. With 
an identification rate of 96% and a false-negative rate of 
5%–10%, it is an effective procedure with low morbidity.3
Although the currently used technique performs well, it 
has drawbacks. The use of radioisotopes is subject to stringent 
regulations on training of staff and handling and disposal 
of radioactive material. Furthermore, the 6 hour half-life 
of 99mTc limits theater scheduling. Most importantly, many 
hospitals in the world do not have access to radioisotopes. 
Consequently, only approximately 60% of the patients in the 
western world and negligible numbers in the rest of the world 
have access to SLNB.10 This has led to the search for other 
techniques, not reliant on the use of radioisotopes.11
Recently the use of a magnetic tracer and a handheld 
magnetometer was evaluated against the “combined tech-
nique” as a radiation-free alternative in two separate clini-
cal trials.12,13 A superparamagnetic iron oxide (SPIO) tracer 
was administered interstitially in the breast, followed by 
identification of the SLNs with a handheld magnetometer. 
The magnetic technique was found to be noninferior to the 
“combined technique” with identification rates of 94.4%– 
98.0%.12,13 However, there was a discordance in SLNs 
identified between the magnetic and combined techniques 
that ranged between 2.0%13 and 6.9%,12 – potentially lead-
ing to false-negative staging with the magnetic technique. 
A smaller study by Shiozawa et al14 used a similar SPIO 
tracer and different magnetometer, comparing SPIO and blue 
dye only – no radioisotope was used. They found an SLN 
identification rate of 90% for the SPIO in combination with 
blue dye, with a discordance rate of 16.7% and demonstrated 
the viability of the technique for performing SLNB in the 
absence of radioisotopes.
Physical and chemical properties including shape, coat-
ing material, and particle size influence the distribution 
of nanoparticles in vivo.15,16 99mTc nanocolloid has a mean 
particle size of approximately 8 nm,17,18 while the particle 
size of the magnetic tracer used for the magnetic technique 
(Sienna+®, Endomagnetics Ltd, UK) is much larger with a 
mean size of approximately 60 nm. Because particle size is 
the most important property influencing lymphatic uptake 
and lymph node retention,19 the identification of different 
SLNs by the two techniques could possibly arise due to 
differences in particle size of the radioisotope and magnetic 
tracer. In order to optimize the clinical application of the 
magnetic technique for SLNB, we evaluated the performance 
of three different-sized SPIO-based formulations – licensed 
for human use – within an in vivo porcine model.
Materials and methods
Tracers/dynamic light scattering
Three SPIO-based licensed formulations with a broad range 
in particle size were used as magnetic tracers in this study. 
Feraheme®/Rienso® (Takeda, Japan) consists of ferumoxytol, 
30 mg Fe/mL and is an Food and Drug Administration–approved 
drug used for the intravenous treatment of iron deficiency anemia 
in adult patients with chronic kidney disease. The particles have 
a magnetic core of maghemite (γ-Fe
2
O
3
) surrounded by a poly-
glucose sorbitol carboxymethylether coating. Sienna+® contains 
27 mg Fe/mL and is a CE-marked magnetic tracer intended to 
mark and locate SLNs in cancer patients. The magnetic core 
consists of magnetite and maghemite (Fe
3
O
4
/γ-Fe
2
O
3
), with a 
carboxydextran coating. Finally, Endorem®/Feridex® (Guerbet, 
France) consisting of ferumoxide, 11.2 mg Fe/mL is licensed 
as a magnetic resonance imaging (MRI) contrast agent for liver 
imaging, with a magnetite core coated with dextran.
All magnetic tracers were diluted to the same iron con-
centration of 11.2 mg Fe/mL to facilitate comparison of per-
formance. Sterile water for injection and a pipette were used 
to prepare the dilutions. The hydrodynamic particle size of 
all tracers was determined by dynamic light scattering using 
a Zetasizer Nano ZS (Malvern Instruments, UK).
animals and surgery
Ethical permission for animal experimentation was granted 
by the Research Institute against Digestive Cancer (IRCAD) 
Ethics Review Board (Strasbourg, France) under reference 
number 38.2012.01.047. A previously developed and vali-
dated porcine model that closely resembles human lymphatic 
drainage was used to evaluate the performance of the dif-
ferent magnetic tracers for SLNB.20 At the IRCAD Institute 
(Strasbourg, France), after induction of anesthesia, mini-pigs 
were injected with one of the three different magnetic tracers 
subcutaneously bilaterally into the areolas of the third ingui-
nal mammary glands. A total of 0.5 mL (5.6 mg Fe) of each 
diluted tracer was injected on each side, in six mini-pigs, for 
each tracer (18 mini-pigs in total; 36 injections).
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Transcutaneous magnetometer measurements using a 
handheld magnetometer (SentiMAG®, Endomagnetics Ltd, 
UK) were undertaken in the inguinal region, where the drain-
ing lymph nodes are located. Measurements were performed 
at 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 
60 minutes, and 240 minutes after administration of the tracer. 
The sites at which uptake of SPIO was successfully detected 
(hotspots) were marked using a permanent marker.
Bilateral SLNB of the inguinal region was undertaken 
4 hours after injection. The incision was made at the site 
of the “magnetic hotspot”. If no “hotspot” was located, a 
blind incision was made in the inguinal region. Postincision, 
the handheld magnetometer was used to identify the SLNs 
in vivo. After identification, lymph nodes demonstrating 
SPIO uptake were removed, and the ex vivo magnetometer 
count was recorded. Lymph nodes with a magnetometer 
count higher than 10% of the “hottest node” were defined 
as SLNs, as was used in the SentiMAG Multicentre Trial,12 
and in accordance with standard clinical practice.21
After completion of the SLNB procedure, a groin node 
clearance was performed. Ex vivo magnetometer measure-
ments were performed on the groin node clearances to 
determine if there were any further SLNs that were missed 
initially. All resected lymph nodes were fixed in formalin and 
sent to the University of Twente (Enschede, The Netherlands) 
for iron quantification and subsequently to King’s College 
London (London, UK) for histopathological evaluation.
Quantification of iron content (vibrating 
sample magnetometry)
The quantification of magnetic tracer in the excised and 
formalin-fixed sentinel lymph nodes was performed using 
vibrating sample magnetometry (VSM) on a Physical Prop-
erties Measuring system (Quantum Design Inc., San Diego, 
CA, USA). An applied magnetic field of 4.0 T was used to 
bring the magnetic iron oxide nanoparticles to saturation. 
The amount of magnetic tracer in the lymph nodes was deter-
mined by comparing the obtained amplitude of the saturation 
magnetization to known calibration samples of each of the 
tracers. The iron content was reported as the mass of iron (Fe) 
in the node, present in the form of maghemite or magnetite. 
VSM allows quantification with 0.5 μg Fe accuracy and is 
nondestructive, which allows subsequent histopathological 
analysis of the same samples.22
histopathology
The nodes were then transferred intact to King’s College 
London (London, UK) where they were embedded in wax, 
thinly sliced, and stained with hematoxylin and eosin and 
with Perl’s Prussian blue for iron. Iron staining within each 
node was graded using a previously validated 5-point grading 
scale (0 = none, 1 = minimal, 2 = mild, 3 = moderate, and 
4 = marked),20 by an experienced pathologist and a second 
observer (SP, BA, or MA).
statistical analysis
We conducted a two-sided test (alpha =0.05) expecting a 
difference of 50 μg (standard deviation [SD] =30) in iron 
content readings between each magnetic tracer. When 
performing a total of 12 procedures (six mini-pigs) for 
each magnetic tracer, these 36 procedures provided us 
with a power of 82% to detect this difference. The relation-
ship between continuous variables was calculated using 
Pearson’s correlation coefficient, associations between 
categorical data using the χ2 test, and associations between 
categorical and continuous variables using analyses of 
variance. All statistical analyses were performed using 
Statistical Analysis Systems (SAS) release 9.3 (SAS Insti-
tute, Cary, NC).
Results
Dynamic light scattering
The Z-averaged hydrodynamic diameter of the magnetic trac-
ers ferumoxytol, Sienna+®, and ferumoxide was determined 
to be 32 nm, 59 nm, and 111 nm, respectively. When the size 
distributions were evaluated graphically (Figure 1), signifi-
cant intratracer heterogeneity in particle size was observed. 
This is reflected by a polydispersity index of 0.179, 0.181, 
and 0.266 for the 32 nm tracer, 59 nm tracer, and 111 nm 
tracer, respectively.
surgery
A total of 36 SLNB procedures were performed in 18 mini-
pigs, and SLN identification was successful in all cases. 
In vivo magnetic hotspots from the draining inguinal lymph 
nodes were successfully identified transcutaneously prior 
to surgical excision using the handheld magnetometer in all 
cases (12/12) for the 32 nm tracer and the 59 nm tracer and 
in all but one case (11/12) for the 111 nm tracer (240 min-
utes after injection). The number of procedures in which a 
transcutaneous hotspot was successfully identified increased 
with time after injection for all three tracers (Figure 2). There 
were 7/12 and 8/12 successfully identified magnetic hotspots 
after 30 minutes using the 32 nm tracer and 111 nm tracer, 
respectively, compared to the 59 nm tracer with magnetic 
hotspots in all cases (12/12).
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Figure 1 Particle size distribution of the three magnetic tracers by dynamic light scattering. 
Note: The particle size (logarithmic scale) is shown against the intensity.
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Figure 2 Relationship between the time after injection of the magnetic tracer and successful identification of transcutaneous hotspot.
A total of 77 SLNs were identified with the handheld 
magnetometer during surgery and subsequently excised. 
Thirty-five SLNs were identified using the 32 nm tracer 
(mean 2.9, SD 1.2), 20 SLNs with the 111 nm tracer (mean 
1.7, SD 0.9), and 22 SLNs (mean 1.8, SD 0.8) with the 59 
nm tracer (Figure 3A). A statistically significant difference 
between the tracer used, and the number of SLNs identified 
was observed overall (P=0.0099) (Figure 3A). More nodes 
per basin were excised with the 32 nm tracer compared to the 
111 nm tracer (P,0.001) and the 59 nm tracer (P=0.03).
The distribution of magnetometer counts demonstrated 
a statistically significant difference among the three tracers 
overall (P,0.0001) (Figure 3B). Multicomparisons demon-
strated that ex vivo magnetometer counts were significantly 
higher with the 59 nm tracer compared to the other two 
tracers (P,0.05).
Quantification of iron content (VSM)
The iron content of the ex vivo SLNs was recorded using 
VSM (Figure 3C). Multiple comparisons between the 
 tracers demonstrated a significant higher iron content for the 
59 nm tracer compared to the 32 nm tracer (P,0.05) only. 
The mean iron content of the SLNs was determined to be 
106 (SD 70) μg, 179 (SD 159) μg, and 265 (SD 206) μg for 
the 32 nm tracer, 111 nm tracer, and 59 nm tracer, respec-
tively. A linear relationship between the iron content of the 
ex vivo SLNs and the handheld magnetometer counts was 
observed for all tracers (Figure 4) – 32 nm tracer (r=0.93; 
P,0.001), 111 nm tracer (r=0.95; P,0.001), and 59 nm 
tracer (r=0.93; P,0.001). Figure 4 demonstrates a difference 
in the sensitivity of the magnetometer for the different tracers. 
The magnetometer count is 2.8 times higher for the 59 nm 
tracer compared to the same amount of iron for the 111 nm 
tracer and 1.3 times higher for the 32 nm tracer compared to 
the 111 nm tracer.
histopathology
The iron was distributed predominantly in the subcapsular 
space peripherally within the cortex, subcapsular space, and 
sinuses (Figure 5). The iron deposition from the 111 nm 
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Figure 3 Boxplots of the relationship between the magnetic tracer and: (A) the number of excised sentinel lymph nodes during surgery; (B) the ex vivo magnetometer 
counts of the excised sentinel lymph nodes; (C) the iron content measured of the excised sentinel lymph nodes by vibrating sample magnetometry. 
Notes: The circle symbols represent outliers; the diamond symbols represent the mean value.
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Figure 4 correlation between the iron content as determined by vibrating sample magnetometry and the ex vivo magnetometer counts for the different magnetic tracers.
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Figure 5 Iron distribution within nodes on histopathology using Perl’s Prussian blue staining for iron and haematoxyline & eosine.
Notes: Magnification 2×, with inserts at 20× magnification. (A) Node containing the 111-nm tracer; (B) node containing the 59 nm tracer; (C) node containing the 32 nm tracer.
tracer was mostly confined to macrophages within the nodes 
(Figure 5A), whereas the 59 nm tracer demonstrated more 
free iron granules (particularly peripherally) (Figure 5B). 
Only very sparse, small islands of iron within macrophages 
were visible for the 32 nm tracer (Figure 5C). There was 
a significant difference in the grade of the iron content of 
excised SLNs between the three different tracers overall 
(P,0.0001) (Figure 6). The amount of iron deposition was 
significantly greater with the 111 nm tracer and 59 nm tracer 
(P,0.05) compared to the 32 nm tracer.
Discussion
Rapid uptake of a magnetic tracer after interstitial injection is 
important to maximize transcutaneous hotspot detection and 
enable injection in the theater suite, facilitating theater sched-
uling. Transcutaneous identification of hotspots was possible 
in most procedures with the 59 nm tracer within 10 minutes of 
the injection and in all except one procedure (with the 111 nm 
tracer) within 240 minutes. Within 30 minutes of injection, 
all hotspots were already identifiable using the 59 nm tracer. 
The greater sensitivity of the magnetometer for the 59 nm 
tracer for a given quantity of iron compared to the other two 
tracers (Figure 4) facilitates hotspot detection.
Discoloration of the skin was present at the injection site 
using all tracers, but this was not quantified during this study. 
Our animal model did not allow to evaluate whether the skin 
discoloration would fade away over time or persist as a tat-
too. Although superficial administration of an SPIO tracer 
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can result in skin tattooing, the current clinical studies using 
SPIO have also not reported adequate follow-up data to fully 
quantify this.12–14 However, any tattooing is anticipated to be 
temporary rather than permanent but may persist for several 
months – similar to that expected for blue dye.23
Any tracer used for SLNB must be retained by the SLNs 
and not pass on to higher echelon nodes in order to avoid 
excessive excision of normal nodes. Within this study, a sta-
tistically significantly greater number of nodes were excised 
using the 32 nm tracer compared to the other two tracers. 
This is a distinct disadvantage of the smaller particle-sized 
magnetic tracer. It suggests that rather than being retained 
within the SLN after entering through the afferent duct, it 
passes through the efferent system and onto higher echelon 
nodes. This is reflected by the small islands of sparsely 
distributed iron within the nodes after the administration of 
the 32 nm tracer on histopathology (Figure 5C). By applying 
the “10% rule” and excising those nodes with only 10% of the 
ex vivo count of the hottest excised node using radioisotope, 
Martin et al24 demonstrated that a mean SLN harvest of 1.96 
nodes was associated with a false-negative rate of 5.8%. In 
the SentiMAG Multicentre Trial using the 59 nm tracer, 
2.02 nodes were excised per procedure using the magnetic 
technique. Excising more than two SLNs during sentinel node 
biopsy is not proven to be beneficial except after primary 
systemic therapy.25 Our data suggest that the small-sized 32 
nm tracer would result in removal of an excessive number 
of normal nodes.
In addition to retention, the accumulation of magnetic 
tracer within the SLNs is essential for intraoperative identifi-
cation. The 59 nm tracer demonstrated statistically significant 
higher ex vivo magnetometer counts compared to the other 
two tracers, but only a statistically significant greater iron 
content over the 32 nm tracer. This is explained by the higher 
sensitivity of the used magnetometer for the 59 nm tracer 
compared to the other two tracers. The higher sensitivity for 
the 59 nm tracer is due to differences in magnetic properties 
of the tracers, arising from differences in size and material 
of the magnetic cores.26
By injecting the magnetic tracer 24 hours before surgery, 
one may be able to improve the iron uptake by the SLNs 
and thereby improve the performance of a tracer. However, 
extending the period between injection and surgery could 
allow adverse SPIO migration to higher echelon nodes 
beyond the SLN. Therefore, this is likely only suitable for 
the larger 111 nm tracer – within this context. However, to 
optimize the time between injection and surgery for each 
tracer, formal assessment of individual tracers for SLNB 
when injected at different times before surgery is needed.
The variation in the accumulation of iron within nodes, 
between different tracers was demonstrated on histopathol-
ogy. There was significantly less iron deposition in nodes 
from the 32 nm tracer compared to the other tracers, with 
only sparse, small islands of iron derived from the 32 nm 
tracer being observed in the nodes. There was no difference 
in the grading of nodes between the 59 nm tracer and the 
111 nm tracer on histopathology. In both cases, the iron was 
distributed in the subcapsular space and sinuses of nodes, 
consistent with previous histopathological studies.20,27 How-
ever, the 111 nm tracer was found to be deposited mainly 
within macrophages – demonstrating its ability to activate 
the mononuclear phagocytic system – compared to the 59 nm 
tracer, which although demonstrating phagocytosis within the 
node also displayed extensive free iron granules peripherally. 
These two processes of activating the mononuclear phago-
cytic system and free iron granule deposition facilitate iron 
accumulation and hence SLN identification using a handheld 
magnetometer.
Different studies have recently evaluated the influence 
of magnetic nanoparticle size on lymphatic uptake in rodent 
models.28–30 Tracers with particle sizes ranging from 4 to 
1,000 nm were used in these studies. The purpose of these 
studies was to optimize tracer uptake in the SLNs to facilitate 
preoperative localization with MRI, rather than intraoperative 
detection. Mori et al30 used 50 nm, 100 nm, 200 nm, and 
1,000 nm–sized particles and concluded that particles of 
200 nm and larger are not suitable in view of lack of uptake 
within 24 hours. Iida et al28 compared the performance of 
4 nm, 8 nm, and 20 nm citrate-coated nanoparticles and con-
cluded that the 20 nm particles were best retained in the SLNs 
and accumulated in the highest concentration. However, the 
20 nm tracer was the largest used, and therefore, it is possible 
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Figure 6 Number of excised sentinel lymph nodes (SLNs) per grade of iron 
distribution, for the three different magnetic tracers.
Note: grade 0 = none, grade 1 = minimal, grade 2 = mild, grade 3 = moderate, 
and grade 4 = marked.
International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1242
Pouw et al
that uptake could be further optimized by increasing the 
particle size. Kjellman et al29 used monodisperse magnetic 
nanoparticles with a polyethylene glycol coating with sizes 
of 15 nm, 27 nm, and 57 nm. The 15 nm particles were 
observed to accumulate in the SLNs the fastest and in the 
highest concentrations. A 15 nm polyethylene glycol–coated 
tracer approved for use in humans is currently not available 
and was not used in our study. Therefore, the efficiency of 
the 15 nm tracer cannot be compared to our results.
During the course of the animal experimentation, there 
were no signs of adverse events developing within the ani-
mals as a consequence of the magnetic tracer administration. 
When magnetic tracers are used as MRI contrast agents, 
doses of 25–100 mg are typically administered. Animal stud-
ies have demonstrated no acute or subacute toxicity when 
150 times this dose has been administered.31 Consequently, 
iron overload would not be possible within this model due 
to the small amounts of iron injected (5.6 mg).
In this study we evaluated the performance in SLNB of 
three magnetic tracers approved for human use. However, 
only the 59 nm tracer is currently CE-marked for the pur-
pose of SLNB in Europe. The 111 nm and 32 nm tracers 
are licensed as an MRI contrast agent and an intravenous 
treatment of iron deficiency anemia, respectively. Apart from 
the dilution of the tracers to standardize iron concentrations, 
no changes were made to the constituents to facilitate the 
translation of the results to clinical practice. The formulation 
of the tracers is very similar; all are aqueous suspensions 
of magnetic nanoparticles in water, with a pH level ranging 
from 5 to 9. The most remarkable difference between the 
tracers is the particle size; however, differences in coating 
and other constituents are also evident. The coating of the 
111 nm tracer and 59 nm tracer are both dextran based 
(dextran and carboxydextran, respectively); however, a 
polyglucose sorbitol carboxymethylether coating is used 
in the 32 nm tracer. Although the coating is known to be a 
factor influencing in vivo nanoparticle distribution, particle 
size was demonstrated to be the most significant factor for 
interstitially administered tracers.19,29,32–34 The poor per-
formance of the polyethylene glycol–coated 32 nm tracer 
compared to the other tracers is therefore likely explained by 
a combination of the particle size distribution and the coat-
ing. The observed differences between the dextran-coated 
tracers are most likely explained by the different particle 
size distributions of these tracers.
Conclusion
Currently, the 59 nm tracer is the best performing magnetic 
nanoparticle tracer, approved for human use, in SLNB with 
a handheld magnetometer. The particles of the 59 nm tracer 
distribute rapidly from the injection site to the SLNs, allowing 
transcutaneous localization within 30 minutes in contrast 
to the 240 minutes for the 32 nm tracer and 111 nm tracer. 
The particles of the 59 nm tracer are retained in the first 
nodes reached in contrast to the particles of the 32 nm tracer. 
Finally, the particles accumulate in high concentrations, 
facilitating intraoperative localization. The rapid distribu-
tion, retention in the first nodes reached, and accumulation in 
high concentration make the 59 nm tracer the most suitable 
magnetic tracer for SLNB.
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